Madrigal Pharmaceuticals Stock Jumps 260%
Madrigal Pharmaceuticals shares jumped over 200% in morning trading!
Market reacted after the company said it say “positive topline results” from a late-stage clinical trial of resmetirom, a treatment for liver conditions.
Tweet on Madrigal Pharma.stock
Madrigal Pharmaceuticals Stock Jumps 260% on Test Results!!
Retail investors reacted to the news as stock skyrocketed in morning trading, after the company said it say "positive topline results!#StocksToBuy #Biotechnology https://t.co/N3ojZAxltX— The_Journalbiz (@the_journalbiz) December 19, 2022
Company official announcement
Madrigal is a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases.
Company’s most advanced clinical candidate, is resmetirom, that has the potential to become the first medication approved for the treatment of patients with non-alcoholic steatohepatitis (NASH) with liver fibrosis according to Madrigal.co
Tweet on the current stock fluctuation
Madrigal Pharmaceuticals shares jumped over 200%
Surge of shares buy during the morning trading,after the company said it say "positive topline results" from a late-stage clinical trial of resmetirom#StocksToBuy #Trending #Biotechnology pic.twitter.com/q6Bc6E9JNV
— The_Journalbiz (@the_journalbiz) December 19, 2022
Factset chart on stock
Madrigal stock was recently up some 260% to about $229. It closed Friday below $64.
The company intends to file a new drug application in the first half of 2023 seeking accelerated approval for resmetirom.
